The global biomaterials market size was valued at USD 204.13 billion in 2025 and is projected to grow from USD 231.65 billion in 2026 to USD 637.06 billion by 2034, registering a CAGR of 13.48% during the forecast period from 2026 to 2034. North America dominated the biomaterials market with a market share of 41.2% in 2025.
Biomaterials are natural or synthetic materials designed to interact safely with biological systems for use in medical and healthcare applications. They are widely used in implants, tissue engineering, wound care, drug delivery, and medical devices.
Download a Free Sample To learn more about this report,
Emergence of Temporally Programmable Biomaterials
Advances in stimuli-responsive polymers and hydrogels are shifting biomaterials toward temporally programmable structures that can change shape, degradation, or function in response to physiological signals; recent research describes 4D biomaterials that respond to stimuli such as temperature, pH, light, and enzymes, supporting controlled changes in tissue engineering and drug-delivery applications.
Shift Toward Immunomodulatory Biomaterials for Controlled Tissue Healing
Greater focus on controlling inflammation during tissue repair is driving the transition toward immunomodulatory biomaterials that actively influence macrophage behavior and the surrounding immune environment; a 2025 study developed a bilayer alginate hydrogel with staged release of IL-10 and angiogenic factors, which reduced inflammation, promoted pro-regenerative macrophage polarization, and accelerated wound closure in diabetic mice.
Increasing Volume of Orthopedic Procedures and Rising Demand for Dental Implants and Tissue Repair Drive Market
The rising volume of joint replacements, bone repairs, and spinal procedures increases demand for biomaterials used in implants, fixation devices, and tissue repair. An aging population and the growing incidence of musculoskeletal disorders contribute to higher orthopedic treatment needs. For example, titanium alloys and porous ceramics are used in hip implants and bone-repair applications because of their strength and biocompatibility. Higher procedure volumes increase procurement of medical-grade metals, ceramics, and polymers, supporting demand across the biomaterials market.
Growing demand for dental implants and tissue-repair procedures increases consumption of biomaterials used for implants, bone grafting, and oral tissue regeneration. Tooth loss, periodontal disease, and rising access to restorative dental care support continued procedure volumes across dental clinics. For example, titanium is widely used in dental implant posts, while hydroxyapatite is used in bone-grafting applications to support bone regeneration. Higher procedure volumes expand demand for biocompatible metals, ceramics, polymers, and regenerative materials. The broader use of dental biomaterials therefore supports market growth across implant and tissue-repair applications.
High Development and Manufacturing Costs and Lack of Standardization in Biomaterial Testing Restrain Market Expansion
Specialized raw materials, advanced processing equipment, extensive testing, and quality-control requirements increase the financial burden of biomaterial development and production. These requirements are particularly challenging for advanced and customized biomaterials, where production processes are more complex. Higher costs can delay commercialization, limit affordability, and slow adoption across cost-sensitive applications.
Differences in testing methods, material characterization, and performance evaluation can make biomaterial results difficult to compare across laboratories and applications. This inconsistency can increase validation requirements and create uncertainty during product development and regulatory assessment. As a result, longer validation processes can delay commercialization and limit broader market adoption.
Development of Biomaterials for Ophthalmic Applications and Increasing Use of Biomaterials in Diagnostic Devices Offer Growth Opportunities
Ophthalmic device manufacturers and biomaterial suppliers can target contact lenses, intraocular lenses, and corneal implants requiring biocompatible materials. Companies such as Bausch + Lomb and Johnson & Johnson MedTech can generate revenue through specialized materials, advanced ophthalmic products, and product-development partnerships.
Diagnostic-device manufacturers and laboratory technology providers can incorporate biomaterials into biosensors and microfluidic platforms that require functional material surfaces. Companies such as Abbott and Danaher can expand revenue through biomaterial-enabled diagnostic products, specialty components, and technology partnerships.
Limited Compatibility with Existing Clinical Workflows and Difficulty in Scaling Biomaterial Manufacturing Hinders Growth
Integrating biomaterial-based products into established surgical, manufacturing, or treatment workflows can require changes in equipment, handling procedures, and clinician training. For example, 3D-printed tissue-engineering scaffolds may require application-specific preparation and implantation protocols, increasing adoption complexity for healthcare providers.
Moving biomaterials from laboratory production to commercial volumes can be difficult because biological materials often require tight control of composition, processing conditions, and batch consistency. For example, collagen-based biomaterials can show source-dependent variations in properties, complicating large-scale production and limiting reliable supply to medical-device manufacturers.
The metallic segment accounted for a share of 38.5% in 2025, supported by its widespread use in orthopedic implants, dental implants, and cardiovascular devices due to high mechanical strength, durability, and biocompatibility. Continued demand for load-bearing implants further supports its leading position in the biomaterials market.
The polymers segment is projected to register a CAGR of 15.3% during the forecast period, driven by growing adoption in drug delivery systems, tissue engineering, and medical devices. Their flexibility, tunable properties, and ability to support minimally invasive applications are increasing their use across advanced healthcare applications. The natural segment is gaining traction due to increasing demand for biocompatible materials derived from collagen, chitosan, alginate, and other biological sources. Their favorable interaction with biological tissues supports adoption in wound healing, tissue engineering, and regenerative medicine. The Ceramics segment is supported by strong demand for dental and orthopedic applications, where high hardness, wear resistance, and biocompatibility are important. Their ability to provide stable performance in demanding implant environments continues to support market adoption.
Request Customizationto receive a tailored report.
The orthopedic segment accounted for a market share of 27.8% in 2025 due to the widespread use of biomaterials in joint replacements, bone fixation devices, spinal implants, and other orthopedic applications requiring biocompatible and mechanically stable materials. The growing need for durable implants and reconstructive procedures supports continued demand for biomaterials in orthopedic applications.
The tissue engineering segment is expected to grow at a CAGR of 16.2%, driven by increasing development of biomaterial-based scaffolds for tissue regeneration and replacement. Advances in regenerative medicine and growing research into engineered tissues are expanding the use of biomaterials for creating structures that support cell growth and tissue repair.
The plastic surgery segment benefits from the use of biomaterials in implants, fillers, grafts, and reconstructive procedures. Growing demand for reconstructive and aesthetic procedures is supporting the use of biocompatible materials designed to provide structural support and tissue compatibility. The neurology segment is supported by the use of biomaterials in neural implants, drug-delivery systems, nerve repair products, and other neurological devices. Increasing research into treatments for neurological disorders and advances in implantable technologies are expanding the application of biomaterials in neurological care. The cardiovascular segment is supported by the use of biomaterials in stents, heart valves, vascular grafts, and other implantable devices requiring biocompatibility and mechanical performance. Growing demand for cardiovascular interventions and implantable devices is supporting the use of biomaterials in this application.
The ophthalmology segment benefits from the use of biomaterials in intraocular lenses, contact lenses, corneal implants, and other ophthalmic devices. Their optical compatibility, flexibility, and biocompatibility support adoption in procedures aimed at restoring or improving visual function. The dental segment is driven by the use of biomaterials in dental implants, bone grafts, restorative materials, and other oral healthcare applications. Increasing demand for tooth replacement and restorative procedures supports the adoption of materials that provide durability, biocompatibility, and integration with surrounding tissue. The wound healing segment is supported by the use of biomaterials in dressings, scaffolds, and advanced wound-care products that promote tissue protection and regeneration. Increasing demand for effective treatment of chronic and complex wounds is supporting the adoption of biomaterial-based wound-care solutions.
Speak to an Analystto discuss market opportunities.
The North America Biomaterials Market accounted for the largest regional share of 41.2% in 2025, supported by advanced healthcare infrastructure, high demand for orthopedic and cardiovascular implants, and increasing adoption of regenerative medicine and tissue-engineering technologies. The region’s strong research focus on engineered biomaterials and scaffold-based approaches for tissue repair is further expanding the use of biomaterials across regenerative medicine and advanced healthcare applications.
The United States biomaterials market is expected to benefit from population aging, with the U.S. Census Bureau projecting one in five Americans to be aged 65 or older by 2030, while older adults are projected to outnumber children by 2034, supporting long-term demand for biomaterials used in orthopedic, cardiovascular, and other medical applications. The Canada biomaterials market is expected to benefit from population aging, with Statistics Canada projecting the share of people aged 65 and older to increase from 19.5% in 2025 to 22.6%–32.5% by 2075, while the population aged 85 and older is projected to rise from 951,833 in 2025 to 3.3–4.2 million by 2075, supporting long-term demand for biomaterials used in medical implants and tissue-repair applications.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe Biomaterials Market is expected to grow at a CAGR of 15.1% during the forecast period 2026–2034, showcasing the fastest-growing regional market, supported by increasing demand for advanced medical materials as Europe’s aging population drives higher prevalence of chronic and age-related diseases, while the European Commission projects EU public healthcare spending to increase from 6.9% of GDP currently to 7.7% by 2070, strengthening demand for innovative healthcare technologies and biomaterial-based medical devices.
The U.K. biomaterials market is expected to benefit from population aging, with the Office for National Statistics projecting the number of people aged 85 and over to increase from 1.75 million in 2024 to 3.6 million by 2049, while the population of pensionable age is projected to rise by 23.7% to 15.3 million, supporting demand for biomaterials used in orthopedic, cardiovascular, and other medical applications.
The Germany biomaterials market is expected to benefit from population aging, with Germany’s Federal Statistical Office projecting 20.5–21.3 million people aged 67 and over by 2038, an increase of 3.8–4.5 million from 2024, while the number of people of working age is projected to decline by at least 4 million by 2070, supporting demand for age-related medical implants and biomaterial-based healthcare solutions. The France biomaterials market is expected to benefit from population aging, with INSEE projecting the number of people aged 65 and over to increase from 15.3 million in 2026 to 21.1 million by 2070, while the population aged 80 and over is projected to rise by 4.6 million to nearly 9 million, supporting demand for biomaterials used in implants, tissue repair, and other medical applications.
The Asia Pacific Biomaterials Market accounted for a market share of 21.8% in 2025, supported by the region’s expanding healthcare needs, with the WHO projecting the share of people aged 60 and above in South-East Asia to increase from 12.2% in 2024 to 22.9% by 2050, while the Western Pacific region’s population aged 65 and above is expected to double by 2050, increasing demand for medical devices, implants, and other biomaterial-based healthcare solutions.
The China biomaterials market is expected to benefit from population aging, with China projected to increase its population aged 60 and above from 21.4% in 2025 to 29.9% by 2035 and 35.8% by 2050, while the population aged 65 and above is projected to reach 22.3% by 2035 and 27.9% by 2050, supporting demand for biomaterials used in implants, medical devices, and other healthcare applications. The Japan biomaterials market is expected to benefit from continued population aging, with Japan’s official projections indicating that the share of people aged 65 and above will increase from 28.6% in 2020 to 38.7% by 2070, while the total population is projected to decline from 126.15 million to 87 million over the same period, increasing the need for age-related healthcare and biomaterial-based medical applications.
The biomaterials market is moderately fragmented, with a mix of multinational healthcare and medical-device companies, specialty biomaterial manufacturers, advanced polymer suppliers, and specialized firms serving applications across orthopedics, cardiovascular devices, dental care, wound care, and tissue engineering. Leading players include Medtronic plc, Evonik Industries AG, Zimmer Biomet Holdings Inc., BASF SE, and Invibio Ltd., which collectively are estimated to account for approximately 25-30% of the global biomaterials market share.
Established players compete primarily on R&D capabilities, material performance, regulatory expertise, product breadth, and established customer relationships. Emerging and specialized players in the biomaterials market ecosystem compete through novel biomaterials, application-specific solutions, customization, advanced processing technologies, and faster innovation cycles.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com